Jane Antony
Jane Antony
Research Fellow, Stanford University
Verified email at stanford.edu
Title
Cited by
Cited by
Year
The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype–specific therapeutic target for ovarian cancer
J Antony, TZ Tan, Z Kelly, J Low, M Choolani, C Recchi, H Gabra, ...
Science Signaling 9 (448), ra97-ra97, 2016
592016
AXL-driven EMT state as a targetable conduit in cancer
J Antony, RYJ Huang
Cancer research 77 (14), 3725-3732, 2017
532017
The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer
J Antony, E Zanini, Z Kelly, TZ Tan, E Karali, M Alomary, Y Jung, K Nixon, ...
EMBO reports 19 (8), e45670, 2018
23*2018
A single cell transcriptomic atlas characterizes aging tissues in the mouse
AO Pisco, N Schaum, A McGeever, J Karkanias, NF Neff, S Darmanis, ...
BioRxiv, 661728, 2019
172019
The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR-and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
E Zanini, LS Louis, J Antony, E Karali, IS Okon, AB McKie, S Vaughan, ...
Molecular Cancer Therapeutics 16 (10), 2246-2256, 2017
172017
Epithelial-to-mesenchymal transition: Lessons from development, insights into cancer and the potential of EMT-subtype based therapeutic intervention
J Antony, JP Thiery, RYJ Huang
Physical biology 16 (4), 041004, 2019
122019
Targeting the AXL signaling pathway in ovarian cancer
RYJ Huang, J Antony, TZ Tan, DSP Tan
Molecular & Cellular Oncology 4 (2), e1263716, 2017
82017
Usp16 modulates Wnt signaling in primary tissues through Cdkn2a regulation
MFC Maddalena Adorno, Benedetta Nicolis di Robilant, Shaheen Shabbir ...
Scientific Reports, 2018
22018
CDK19 is a Regulator of Triple-Negative Breast Cancer Growth
RW Hsieh, AH Kuo, FA Scheeren, MA Zarnegar, SS Sikandar, J Antony, ...
bioRxiv, 317776, 2018
22018
Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions
JR Birtley, M Alomary, E Zanini, J Antony, Z Maben, GC Weaver, ...
Nature communications 10 (1), 1-16, 2019
12019
Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers
J Antony, E Zanini, JR Birtley, H Gabra, C Recchi
Cancer Gene Therapy, 1-9, 2020
2020
Sensitization of Cancer Cells via Non‐Viral Delivery of Apoptosis Inducing Proteins Using a Cationic Bolaamphiphile
K Narayanan, M Khan, B Gopalan, J Antony, T Das, YY Yang, ACA Wan
Biotechnology journal 14 (3), 1800020, 2019
2019
TGF-beta family protein LEFTY, a physiological Dual-SMAD inhibitor, promotes long-term proliferation of normal and malignant mammary cells.
J Antony, M Zabala, N Lobo, L Heitink, J Lam, N Parashurama, M Adorno, ...
MOLECULAR BIOLOGY OF THE CELL 29 (26), 2018
2018
Abstract NTOC-116: THE TUMOUR SUPPRESSOR PROTEIN OPCML ACTS AS A SENSITIZING AGENT IN ANTI–EGFR/HER2 THERAPY AND CISPLATIN TREATMENT IN OVARIAN CANCER
E Zanini, LS Louis, J Antony, I Okon, AB McKie, C Recchi, H Gabra
Clinical Cancer Research 23 (11 Supplement), NTOC-116-NTOC-116, 2017
2017
The phosphatase PTPRG inactivates AXL? sequestered in membrane lipid domains by the tumor suppressor OPCML.
J Antony, E Zanini, Z Kelly, R Huang, J Thiery, H Gabra, C Recchi
MOLECULAR BIOLOGY OF THE CELL 28, 2017
2017
297O Stratifying ovarian cancer based on AXL signaling for therapeutic targeting
RYJ Huang, J Antony, TZ Tan, J Low, M Choolani, JP Thiery
Annals of Oncology 27 (suppl_9), 2016
2016
THE PIVOTAL ROLE OF AXL/GAS6 SIGNALING NODE IN THE MESENCHYMAL SUBTYPE OF OVERIAN CANCER, AND ITS MODULATION BY THE TUMOR SUPPRESSOR OPCML
J Antony
2016
Sustained Gas6/AXL signaling network in the mes subtype of ovarian cancer as a molecular subtype specific therapeutic target.
RYJ Huang, J Antony, TZ Tan, Z Kelly, H Gabra, C Recchi, JP Thiery
Journal of Clinical Oncology 34 (15_suppl), e17084-e17084, 2016
2016
The receptor tyrosine kinase AXL modulates oncogenic signaling and epithelial mesenchymal transition in epithelial ovarian cancer
J Antony, TZ Tan, A Paterson, C Recchi, H Gabra, JP Thiery, RYJ Huang
CLINICAL CANCER RESEARCH 21, 2015
2015
Abstract POSTER-BIOL-1301: The receptor tyrosine kinase AXL modulates oncogenic signaling and epithelial mesenchymal transition in epithelial ovarian cancer
J Antony, TZ Tan, A Paterson, C Recchi, H Gabra, JP Thiery, RYJ Huang
Clinical Cancer Research 21 (16 Supplement), POSTER-BIOL-1301-POSTER-BIOL-1301, 2015
2015
The system can't perform the operation now. Try again later.
Articles 1–20